<p>French drugmaker Sanofi again raised its profit guidance for 2021 as its blockbuster eczema drug Dupixent and flu vaccines helped it beat market forecasts in the third quarter.</p>.<p>The group, which is hoping for a comeback after losing ground in the Covid-19 jab race, said sales in the three months to September grew 10.1% to 10.4 billion euros ($12.1 billion) while earnings per share came in at 2.18 euros. The latter compared with a 1.99 euros average forecast in an analyst consensus provided by the company.</p>.<p>Sanofi now expects earnings per share to climb by around 14% at constant currencies this year, up from a previous, already improved estimate for 12% growth released in July.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/business/sanofi-to-buy-us-mrna-partner-translate-bio-in-32-bn-deal-1015737.html">Sanofi to buy US mRNA partner Translate Bio in $3.2 bn deal</a></strong></p>.<p>Despite being one of the biggest makers of vaccines in the world by sales before the Covid-19 pandemic, Sanofi was beaten by newcomers who used newer mRNA technology to immunise people against coronavirus.</p>.<p>Sanofi stopped trials of its own mRNA Covid-19 jab last month, saying that it was too late to enter a market dominated by rivals BioNTech/Pfizer and Moderna.</p>.<p>It is instead focusing on efforts with British partner GlaxoSmithKline to bring another Covid-19 vaccine candidate to market based on the more conventional protein-based approach, where mass trials are ongoing.</p>.<p>Sanofi's Finance chief Jean-Baptiste de Chatillon told reporters the group was still expecting results from those trials by the end of the year.</p>.<p>($1 = 0.8618 euros)</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>French drugmaker Sanofi again raised its profit guidance for 2021 as its blockbuster eczema drug Dupixent and flu vaccines helped it beat market forecasts in the third quarter.</p>.<p>The group, which is hoping for a comeback after losing ground in the Covid-19 jab race, said sales in the three months to September grew 10.1% to 10.4 billion euros ($12.1 billion) while earnings per share came in at 2.18 euros. The latter compared with a 1.99 euros average forecast in an analyst consensus provided by the company.</p>.<p>Sanofi now expects earnings per share to climb by around 14% at constant currencies this year, up from a previous, already improved estimate for 12% growth released in July.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/business/sanofi-to-buy-us-mrna-partner-translate-bio-in-32-bn-deal-1015737.html">Sanofi to buy US mRNA partner Translate Bio in $3.2 bn deal</a></strong></p>.<p>Despite being one of the biggest makers of vaccines in the world by sales before the Covid-19 pandemic, Sanofi was beaten by newcomers who used newer mRNA technology to immunise people against coronavirus.</p>.<p>Sanofi stopped trials of its own mRNA Covid-19 jab last month, saying that it was too late to enter a market dominated by rivals BioNTech/Pfizer and Moderna.</p>.<p>It is instead focusing on efforts with British partner GlaxoSmithKline to bring another Covid-19 vaccine candidate to market based on the more conventional protein-based approach, where mass trials are ongoing.</p>.<p>Sanofi's Finance chief Jean-Baptiste de Chatillon told reporters the group was still expecting results from those trials by the end of the year.</p>.<p>($1 = 0.8618 euros)</p>.<p><strong>Watch the latest DH Videos here:</strong></p>